Антифосфолипидные антитела и их клиническое значение

УДК 616-097.77-07

Аннотация

Резюме. Обзор посвящён антифосфолипидным антителам (аФЛ) и их клинико-диагностической ценности. Рассматриваются вопросы стандартизации методов исследования аФЛ, в частности твердофазных тест-систем, одним из представителей которых является хемилюминесцентый анализ. Обсуждаются патогенетические аспекты антифосфолипидного синдрома (АФС) и описываются пути влияния аФЛ на различные компоненты гемостаза. Дается подробная характеристика β2-гликопротеина 1 (β2-ГП1) с описанием доменов. Подробно изучены клинические проявления и взаимосвязь «экстра»- критериальных аФЛ: IgA антител к кардиолипину (IgA-аКЛ), IgA антител к β2-ГП1 (IgA-аβ2-ГП1), антител к домену I β2-ГП1 (аβ2-ГП1-DI), антител к комплексу фосфатидилсерин–протромбин и аФЛ, не входящих в Сиднейские диагностические критерии АФС.

Литература:

1. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71. DOI: 10.14412/1995–4484–2014– 56–71. 

2. Miyakis S., Lockshin M.D., Atsumi T. et al. International con- sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. DOI: 10.1111/j.1538–7836.2006.01753.x. 

3. Pignatelli P., Ettorre E., Menichelli D. et al. Seronegative antiphos- pholipid syndrome: refining the value of «non-criteria» antibo- dies for the diagnosis and clinical management. Haematologica. 2020;105(3):562–72. DOI: 10.3324/haematol.2019.221945. 

4. Roubey R.A.S. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996;39(9):1444–54. DOI: 10.1002/ art.1780390903. 

5. Волкова М.В., Кундер Е.В., Генералов И.И., Роггенбук Д. Анти- фосфолипидные антитела: современные представления о патогенетическом действии и лабораторной диагностике. Вестник Витебского государственного медицинского универси- тета. 2015;14(3):6–15. 

6. Harris E.N., Gharavi A.E., Boey M.L. et al. Anticardiolipin antibo- dies: detection by radioimmunoassay and association with throm- bosis in systemic lupus erythematosus. Lancet. 1983;2(8361):1211– DOI: 10.1016/S0140–6736(83)91267–9. 

7. Urbanus R.T., Philip G de G. Antiphospholipid antibodies — we are not quite there yet. Blood Rev. 2011;25(2):97–106. DOI: 10.1016/j. 2010.12.001. 

8. Sciascia S., Amigo M.–C., Roccatello D., Khamashta M. Diagnos- ing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548–60. DOI: 10.1038/nrrheum.2017.124. 

9. Devreese K., Hoylaerts M.F. Laboratory diagnosis of the antiphos- pholipid syndrome: a plethora of obstacles to overcome. Eur J Hae- matol. 2009;83(1):1–16. DOI: 10.1111/j.1600–0609.2009.01243.x.
10. Persijn L., Decavele A.S., Schouwers S., Devreese K. Evaluation of a new set of automated chemiluminescense assays for anticar- diolipin and anti-beta2-glycoprotein I antibodies in the labora- tory diagnosis of the antiphospholipid syndrome. Thromb Res. 2011;128(6):565–9. DOI: 10.1016/j.thromres.2011.04.004.
11. Van Hoecke F., Persijn L., Decavele A.S., Devreese K. Performance of two new, automated chemiluminescence assay panels for anti- cardiolipin and anti-beta2-glycoprotein I antibodies in the lab- oratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34(6):630–40. DOI: 10.1111/j.1751–553X.2012.01448.x.
12. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтеpра, 2004. 434 с. Nasonov E.L. Antiphospholipid syndrome. Moscow: Litterra, 2004. 434 pp. (In Russ.).

13. Решетняк Т.М., Вавилова Т.В. Клинико-лабораторные кри- терии антифосфолипидного синдрома — что нужно знать практическому врачу (Лекция). Клиническая лабораторная диагностика. 2010;(11):13–20. 
14. de Groot P.G., Urbanus R.T. Antiphospholipid syndrome — not a noninflammatory disease. Semin Thromb Hemost. 2015;41(6):607– DOI: 10.1055/s-0035–1556725.

15. Vreede A.P., P.L. Bockenstedt, Knight J.S. Antiphospholipid syn- drome: an update for clinicians and scientists. Curr Opin Rheu- matol. 2017;29(5):458–66. DOI: 10.1097/BOR.0000000000000410.
16. Conti F., Sorice M., Circella A. et al. Beta-2-glycoprotein I expres- sion on monocytes is increased in anti-phospholipid antibody syn- drome and correlates with tissue factor expression. Clin Exp Immu- nol. 2003;132(3):509–16. DOI: 10.1046/j.1365–2249.2003.02180.x.
17. Caronti B., Calderaro C., Alessandri C. et al. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999;115(1):214–9. DOI: 10.1046/j.1365–2249.1999.00770.x.
18. Muller-Calleja N., Lackner K.J. Mechanisms of cellular activa- tion in the antiphospholipid syndrome. Semin Thromb Hemost. 2018;44(5):483–92. DOI: 10.1055/s-0036–1597290. 

19. Pierangeli S.S., Vega-Ostertag M.E., Raschi E. et al. Toll-like recep- tor and antiphospholipid mediated thrombosis: in vivo Ann Rheum Dis. 2007;66(10):1327–33. DOI: 10.1136/ard.2006.065037. 

20. Xie H., Kong X., Zhou H. et al. TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome. Clin Immunol. 2015;160(2):198–210. DOI: 10.1016/j.clim.2015.05.017. 

21. Laplante P., Fuentes R., Salem D. et al. Antiphospholipid anti- body-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. Lupus. 2016;25(2):162–76. DOI: 1177/0961203315603146.
22. Terrisse A.D., Laurent P.A., Garcia C. et al. The class I phos- phoinositide 3-kinases alpha and beta control antiphospho- lipid antibodies-induced platelet activation. Thromb Haemost. 2016;115(6):1138–46. DOI: 10.1160/TH15–08–0661. 

23. Wu M., Barnard J., Kundu S., McCrae K.R. A novel pathway of cel- lular activation mediated by antiphospholipid antibody-induced extracellular vesicles. J Thromb Haemost. 2015;13(10):1928–40. DOI: 10.1111/jth.13072.
24. Benagiano M., Gerosa M., Romagnoli J. et al. β2 glycoprotein I recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome. J Immunol. 2017;198(7):2640–8. DOI: 10.4049/jimmunol.1600305. 

25. Ulrich V., Gelber S.E., Vukelic M. et al. ApoE receptor 2 medi- ation of trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice. Arthritis Rheu- matol. 2016;68(3):730–9. DOI: 10.1002/art.39453. 

26. Arachchillage D.R.J., Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017;178(2):181–95. DOI: 10.1111/bjh.14632. 

27. Christodoulou C., Sangle S., D’Cruz D.P. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology (Oxford). 2007;46(6):907–10. DOI: 10.1093/rheumatology/kem040. 

28. Canaud G., Bienaimé F., Noël L.-H. et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant. 2010;10(9):2051– DOI: 10.1111/j.1600–6143.2010.03233.x. 

29. Fangtham M., Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013;15(9):360. DOI: 10.1007/s11926–013–0360–0. 

30. Lockshin M.D., Kim M., Laskin C.A. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64(7):2311–8. DOI: 10.1002/ 
34402. 

31. Bertolaccini M. L., Hughes G. R., Khamashta M. A. Revisiting 
antiphospholipid antibodies: from targeting phospholipids to 
phospholipid binding proteins. Clin Lab. 2004;50(11–12):653–65. 

32. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat 
Rev Rheumatol. 2011;7(6):330–9. DOI: 10.1038/nrrheum.2011.52. 

33. Schultze H.E. Glycoproteins of human plasma. Bull Schweiz Akad 
Med Wiss. 1961;17:77–91. PMID: 14039075. [Article in German]. 

34. Pelkmans L., de Laat B. Antibodies against domain I of begly- coprotein I: the one and only? Lupus. 2012;21()7:769–72. DOI: 
1177/0961203312437439. 

35. Chighizola C. B., Gerosa M., Meroni P. L. New tests to detect 
antiphospholipid antibodies: anti-domain I beta-2-glycoprotein- I antibodies. Curr Rheumatol Rep. 2014;16(2):402. DOI: 10.1007/ s11926–013–0402–7. 

36. Agar C., de Groot P.G., Morgelin M. et al. β2-glycoprotein I: a novel component of innate immunity. Blood. 2011;117(25):6939–47. DOI: 1182/blood-2010–12–325951. 

37. Laplante P., Amireault P., Subang R. et al. Interaction of β2-glyco- protein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem. 2011;286(49):42494–503. DOI: 10.1074/jbc.M111.230383. 

38. Ioannou Y., Rahman A. Domain I of beta2-glycoprotein I: its role 
© Чельдиева Ф.А., Решетняк Т.М., Лила А.М., 2021 © ООО «Гемостаз и Реология», 2021 as an epitope and the potential to be developed as a specific tar- get for the treatment of the antiphospholipid syndrome. Lupus. 2010;19(4):400–5. DOI: 10.1177/0961203309360544.
39. Pengo V., Ruffatti A., Tonello M. et al. Antibodies to domain 4/5 (Dm4/5) of β2-glycoprotein 1 (β2GP1) in different antiphospho- lipid (aPL) antibody profiles. Thromb Res. 2015;136(1):161–3. DOI: 10.1016/j.thromres.2015.04.031.
40. de Laat B., Pengo V., Pabinger I. et al. The association between cir- culating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Hae- most. 2009;7(11):1767–73. DOI: 10.1111/j.1538–7836.2009.03588.x.
41. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycopro- tein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542– 6. DOI: 10.1073/pnas.95.26.15542.
42. Палькеева М. Е., Сидорова М. В., Кузнецова Т. В. и др. Син- тез и исследование антигенных свойств пептидных фраг- ментов бета2-гликопротеина-I. Биоорганическая химия. 1996;22(9):678–85. 
43. George J., Gilburd B., Hojnik M. et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in anti- body binding. J Immunol. 1998;160:3917–23.
44. Pericleous C., Ferreira I., Borghi O. et al. Measuring IgA anti- β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016;11(6): e0156407. DOI: 10.1371/journal.pone.0156407.
45. McNeely P.A., Dlott J. S., Furie R. A. et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Hae- most. 2001;86(2):590–5.
46. Reddel S.W., Wang Y.X., Sheng Y.H., Krillis S.A. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun. 2000;15(2):91–6. DOI: 10.1006/ 2000.0427.
47. Iverson G.M., Reddel S., Victoris E.J. et al. Use of single point muta- tions in domain I of β2-glycoprotein I to determine fine anti- body specificity of antiphospholipid autoantibodies. J Immunol. 2002;169(12):7097–103. DOI: 10.4049/jimmunol.169.12.7097.
48. Ioannou Y., Pericleous C., Giles I. et al. Binding of antiphos- pholipid antibodies to discontinuous epitopes on domain I of human beta (2)-glycoprotein I: mutation studies including res- idues R39 to R43. Arthritis Rheum. 2007;56(1):280–90. DOI: 10.1002/art.22306.
49. Agar C., van Os G.M., Morgelin M. et al. β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336–43. DOI: 1182/blood-2009–12–260976.
50. Bouma B., de Groot P.G., van den Elsen J.M. et al. Adhesion mech- nism of human beta 2-glycoprotein I to phospholipid based on its crystal structure. EMBO J. 1999;18(19):5166–74. DOI: 10.1093/ emboj/18.19.5166.
51. Schwarzenbacher R., Zeth K., Diederichs K. et al. Crystal struc- ture of human beta2-glyoprotein I: implications for phospho- lipid binding and the antiphospholipid syndrome. EMBO J. 1999;18(22):6228–39. DOI: 10.1093/emboj/18.22.6228.
52. Hammel M., Kriechbaum M., Gries A. et al. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small- angle x-ray scattering. J Mol Biol. 2002;321:85–97. DOI: 10.1016/ s0022–2836(02)00621–6.
53. de Laat B., Derksen R.H., van Lummel M. et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916–24. DOI: 10.1182/blood-2005–05–1943.
54. de Laat B., van Berkel M., UrbanusR.T. et al. Immune responses against domain I of b(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011;63(12):3960– DOI: 10.1002/art.30633.
55. Giannakopoulos B., Krillis S.A. The pathogenesis of the antiphos- pholipid syndrome. N Eng J Med. 2013;368(11):1033–44. DOI: 10.1056/NEJMra1112830. 

56. Fischetti F., Durigutto P., Pellis V. et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement depen- dent and requires a priming factor. 2005;106:2340–6. DOI: 10.1182/blood-2005–03–1319. 

57. Mahler M., Albesa R., Zohoury N. et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemilumines- cence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus. 2016;25(8):911– DOI: 10.1177/0961203316640366. 

58. Radin M., Cecchi I., Roccatello D. et al. Prevalence and throm- botic risk assessment of anti-β2 glycoprotein I domain I antibo- dies: a systematic review. Semin Thromb Hemost. 2018;44(5):466– 74. DOI: 10.1055/s-0037–1603936. 

59. Bertolaccini M.L., Atsumi T., Contreras A.E. et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheuma- tol. 2001;28(12):2637–43. 

60. Andreoli L., Nalli C., Motta M. et al. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain4/5: might it be the reason for their innocent’ profile? Ann Rheum Dis. 2011;70(2):380–3. DOI: 10.1136/ard.2010.137281. 

61. Arvieux J., Renaudineau Y., Mane I. et al. Distinguishing fea- tures of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Hae- most. 2002;87(4):599–605. 

62. Avcin T., Ambrozic A., Kuhar M. et al. Anticardiolipin and anti- beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001;40(5):565–73. DOI: 10.1093/rheumatology/40.5.565. 

63. Ambrozic A., Avicin T., Ichikawa K. et al. Anti-beta(2)-glycopro- tein I antibodies in children with atopic dermatitis. Int Immunol. 2002;14(7):823–30. DOI: 10.1093/intimm/dxf043. 

64. Filippidou N., Krashias G., Pericleous C. et al. The association be- tween IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and domain I of β2-glycoprotein I with disease profile in pa- tients with multiple sclerosis. Mol Immunol. 2016;75:161–7. DOI: 10.1016/j.molimm.2016.05.022. 

65. ,NormanG.L.,MeroniP.L.,KhamashtaM.Autoantibo- dies to domain 1 of beta 2 glycoprotein 1: a promising candidate bio- marker for risk management in antiphospholipid syndrome. Auto- immun Rev. 2012;12(2):313–7. DOI: 10.1016/j.autrev.2012.05.006. 

66. Serrano M., Martinez-Flores J.A., Norman G.L. et al. The IgA iso- type of anti-beta2 glycoprotein I antibodies recognizes epitopes in domains 3, 4, and 5 that are located in a lateral zone of the molecule (L-Shaped). Front Immunol. 2019;10:1031. DOI: 10.3389/ fimmu.2019.01031. 

67. Lakos G., Favaloro E.J., Harris E.N. et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I tes- ting: report from the 13th International Congress on Antiphospho- lipid Antibodies. Arthritis Rheum. 2012;64(1):1–10. DOI: 10.1002/ art.33349. 

68. Brusch A. The significance of anti-beta-2-glycoprotein I antibod- ies in antiphospholipid syndrome. Antibodies (Basel). 2016;5(2):16– DOI: 10.3390/antib5020016. 

69. Murthy V., Rohan Willis R., Romay-Penabad Z. et al. Value of iso- lated IgA anti-β2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013;65(12):3186– 93. DOI: 10.1002/art.38131. 

70. Tortosa C., Cabrera-Marante O., Serrano M. et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti β2 glycoprotein-I antibodies. PloS One. 2017;12(7): e0178889. DOI:10.1371/journal.pone.0178889.

71. Litvinova E., Darnige L., Kirilovsky A. et al. Prevalence and sig- nificance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971. DOI: 10.3389/fimmu.2018.02971.

72. Bertolaccini M.L., Sanna G. The clinical relevance of noncri- teria antiphospholipid antibodies. Semin Thromb Hemost. 2018;44(5):453–57. DOI: 10.1055/s-0037–1601328.

73. Molina J.F., Gutierrez-Urenã S., Molina J. et al. Variability of anti- cardiolipin antibody isotype distribution in 3 geographic popu- lations of patients with systemic lupus erythematosus. J Rheu- matol. 1997;24(2):291–6.

74. Diri E., Cucurull E., Gharavi A.E. et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and aβ2 glycopro- tein-I is the most frequent isotype. Lupus. 1999;8(4):263–8. DOI: 10.1191/096120399678847812.

75. Yamada H., Tsutsumi A., Ichikawa K. et al. IgA-class anti-beta2-gly- coprotein I in women with unexplained recurrent sponta- neous abortion. Arthritis Rheum. 1999;42(12):2727–8. DOI: 10.1002/1529–0131(199912)42:12<2727::AID-ANR33>3.0.CO;2-Q.
76. Lee R. M., Branch D. W., Oshiro B. T. et al. Immunoglobulin A anti-beta2-glycoprotein antibodies are elevated in women with unexplained recurrent spontaneous abortion and unex- plained fetal death. Am J Obstet Gynecol. 2001;185(3):748–53. DOI: 1067/mob.2001.117659.

77. Meijide H., Sciascia S., Sanna G. et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013;12(3):421– 5. DOI: 10.1016/j.autrev.2012.08.002.

78. Radin M., Ugolini-Lopes M.R., Sciascia S. Andrade D. Extra-cri- teria manifestations of antiphospholipid syndrome: Risk assess- ment and management. Semin Arthritis Rheum. 2018;48(1):117–20. DOI: 10.1016/j.semarthrit.2017.12.006.

79. Otomo K., Atsumi T., Amengual O. et al. Efficacy of the antiphos- pholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504–12. DOI: 10.1002/art.33340.

80. Amengual O., Forastiero R., Sugiura-Ogasawara M. et al. Evalua- tion of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2017;26:266–76. DOI: 10.1177/0961203316660203.

81. Pregnolato F., Chighizola C.B., Encabo S. et al. Anti-phosphatidyl- serine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013;56(2–3):432–8. DOI: 10.1007/s12026– 013–8421-z.

82. Bertolaccini M.L., Atsumi T., Koike T. et al. Antiprothrombin anti- bodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Hae- most. 2005;93(2):289–97. DOI: 10.1160/TH04–06–0382.

83. Sciascia S., Murru V., Sanna G. et al. Clinical accuracy for diag- nosis of antiphospho- lipid syndrome in systemic lupus erythe- matosus: evaluation of 23 possible combinations of antiphospho- lipid antibody specificities. J Thromb Haemost. 2012;10(12):2512–8. DOI: 10.1111/jth.12014.

84. Tonello M., Mattia E., Favaro M. et al. IgG phosphatidylserine/pro- thrombin antibodies as a risk factor of thrombosis in antiphos- pholipid antibody carriers. Thromb Res. 2019;177:157–60. DOI: 10.1016/j.thromres.2019.03.006.

85. Ganapati A., Goel R., Kabeerdoss J. et al. Study of clinical util- ity of antibodies to phosphatidylserine/prothrombin complex in Asian-Indian patients with suspected APS. Clin Rheumatol. 2019;38(2):545–53. DOI: 10.1007/s10067–018–4301–1.

86. Zigon P., Podovsovnik A., Ambrozic A. et al. Added value of non- criteria antiphospholipid antibodies for antiphospholipid syn- drome: lessons learned from year-long routine measurements. Clin Rheumatol. 2019;38(2):371–78. DOI: 10.1007/s10067–018– 4251–7.